To undertake a budget impact analysis of Aducanumab - a disease-modifying therapy to treat mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) that potentially prevents or delays the progression to dementia – on the societal costs of AD in Australia using a Markov decision-analytic model.
|Effective start/end date
|25/08/20 → 31/12/20
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.